BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 19, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Tango’s USP1 inhibitor TNG-348 cleared to enter clinic for BRCA1/2 mutant and other HRD+ cancers
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Tango’s USP1 inhibitor TNG-348 cleared to enter clinic for BRCA1/2 mutant and other HRD+ cancers
Sep. 7, 2023
No Comments
Tango Therapeutics Inc. has received FDA clearance of its IND application for TNG-348...
BioWorld Science
Regulatory
Cancer
FDA
IND
